Acetylcholine Iontophoresis
PreclinicalSmall molecule
Acetylcholine Iontophoresis is one of 15 small molecule programs targeting Leprosy. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Leprosy
#DrugCompanyPhaseTrials
1Rifadin
SanofiApproved
Lamprene
NovartisApproved
Neoral
NovartisApproved
Avlosulfon
AAlmirall, S.A.
Approved
Thalomid
Bristol-Myers SquibbPhase 2
Rifampicin
Boehringer IngelheimPhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Glucophage
EMD SeronoPhase 2
Sirturo
WWim Janssens
Phase 2
Ciclosporin
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acetylcholine Iontophoresis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details